drug
alectinib
Marketedupdated 6mo agoby F. Hoffmann-La Roche Ltd
Approvedcommunity read0 votes
indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying alectinib
- phase2A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- phase2Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
- phase3Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
- —Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- phase3Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- phase2Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- phase3A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- phase2A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 18, 2027
150 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Apr 24, 2035formulationUS 10350214
- Apr 24, 2035formulationUS 11433076
- Mar 4, 2032formulationUS 9365514
- May 29, 2031compositionUS 91269314.5y
- Jun 9, 2030formulationUS 94409223.6y
FDA exclusivities (2)
- Apr 18, 2031ODE-477Orphan Drug (7y)4.4y
- Apr 18, 2027I-947Indication (3y)150d
News(2)
- FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSKThe FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.biopharma_dive · 7h ago
- GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buyNelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.biospace · 8h ago
Data sources
last refreshed 59m ago
Found something off?
comments(0)
5-min edit window · permanent after that